Global Vaccine Market by Technology & Types, Various Classes & Indications 2013-2022

DUBLIN, November 13, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/g422mm/vaccine_market_by) has announced the addition of the "Global Vaccine Market by Technology & Types, Various Classes & Indications 2013-2022" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The global vaccine technology market is anticipated to reach around $84 billion by 2022, growing at a CAGR of 11.36%.

The vaccine market is divided by technology class (Live/Attenuated, Toxoid, Conjugate, Sub-Unit, Recombinant Vector, DNA, Synthetic, and Dentritic Vaccines), types (Preventive and Therapeutic), end users (Pediatric and Adult), disease indication (Infectious Diseases, Cancer, Allergies, and Others - Diabetes, Cardiovascular Diseases), and geography (North America, Europe, Asia, and Rest of the World). Furthermore, each technology class, type, end user, and disease indication segment is broken down by geography, with exhaustive revenue analysis for the entire forecast period. Of the above mentioned disease indication segments, infectious disease vaccines are the largest revenue segment; however, cancer vaccines will be the fastest-growing segment with the highest CAGR.

The potential growth of the market is attributed towards therapeutic vaccines, allergy vaccines, and emerging-disease vaccines. Improved understanding of immunology, new technological breakthroughs in the development of a new class of vaccines, namely, recombinant vector vaccines, DNA vaccines, and dendritic vaccines coupled with excellent distribution channels are propelling the growth of this market. Furthermore, a large population base in emerging economies and a high prevalence of diseases is driving the market, which is expected to remain consistent in the coming years.

Largely popular as the biological preparation exclusively for the prevention of diseases, vaccines are now emerging as therapeutic agents for improving the immune system. This is adding a new dimension to the vaccine industry, opening doors for the treatment of various ailments, especially cancer, cardiovascular disease, diabetes, and smoke cessation. These opportunities have also paved the way for the entry of new companies and for the development of newer technology platforms. Furthermore, new emerging approaches to vaccine development such as reverse vaccinology, personalized vaccinomics, and systems vaccinomics are paving the way for the development of new effective vaccines capable of addressing current and emerging infectious diseases and cancers.

North America (42%) is a significant contributor, followed by Europe (36%), due to the highly structured healthcare reimbursement policies and the high purchasing power of costly vaccines. The new markets for vaccine are expected to grow at a vigorous pace in emerging economies such as China, India, and other regions in Asia-Pacific and untapped markets in Europe due to their growing GDP, healthcare costs, and rising demand for safe and cost-effective diagnostics and therapeutics.

Scope of the Report

Technology Class
- Live
- Toxoid
- Conjugate
- Sub-Unit
- Recombinant Vector Vaccines
- DNA Vaccines
- Synthetic Vaccines
- Dentritic Vaccines

Types
- Preventive
- Therapeutic

End Users
- Pediatric
- Adult

Disease Indication
- Infectious Diseases
- Cancer
- Allergies
- Others

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Technology Snapshot

4 Vaccine Research Portfolio

5 Value Chain Analysis

6 Market Landscape

7 Technology Adoption

8 Investment Analysis

9 Competitive Landscape

10 Regulatory Landscape

11 Patent Analysis

12 Analyst Recommendations

13 Company Profiles

- Aduro Biotech
- Alphavax
- Antigen Express, INC
- Bavarian Nordic
- Biondvax Pharmaceuticals LTD
- Genticel
- Glaxo Smithkline PLC
- Immune Targeting Systems (ITS)
- Immunobiology LTD
- Liquidia Technologies
- Merck & CO, INC
- Novartis AG
- Pfizer, INC
- Prokarium
- Sanofi

For more information visit http://www.researchandmarkets.com/research/g422mm/vaccine_market_by.

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

SOURCE Research and Markets